1. Home
  2. NAT vs REPL Comparison

NAT vs REPL Comparison

Compare NAT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nordic American Tankers Limited

NAT

Nordic American Tankers Limited

HOLD

Current Price

$8.00

Market Cap

1.7B

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$12.94

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAT
REPL
Founded
1995
2015
Country
Bermuda
United States
Employees
18
465
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.2B
IPO Year
1997
2018

Fundamental Metrics

Financial Performance
Metric
NAT
REPL
Price
$8.00
$12.94
Analyst Decision
Sell
Hold
Analyst Count
2
9
Target Price
$4.00
$5.67
AVG Volume (30 Days)
4.5M
1.9M
Earning Date
05-28-2026
05-21-2026
Dividend Yield
8.50%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$77.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$525.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$1.50
52 Week High
$8.33
$16.33

Technical Indicators

Market Signals
Indicator
NAT
REPL
Relative Strength Index (RSI) 68.21 43.52
Support Level $5.42 $12.40
Resistance Level N/A $16.02
Average True Range (ATR) 0.28 0.72
MACD 0.08 -0.34
Stochastic Oscillator 75.80 15.14

Price Performance

Historical Comparison
NAT
REPL

About NAT Nordic American Tankers Limited

Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: